Latest & greatest articles for multiple sclerosis

The Trip Database is a leading resource to help health professionals find trustworthy answers to their clinical questions. Users can access the latest research evidence and guidance to answer their clinical questions. We have a large collection of systematic reviews, clinical guidelines, regulatory guidance, clinical trials and many other forms of evidence. If you wanted the latest trusted evidence on multiple sclerosis or other clinical topics then use Trip today.

This page lists the very latest high quality evidence on multiple sclerosis and also the most popular articles. Popularity measured by the number of times the articles have been clicked on by fellow users in the last twelve months.

What is Trip?

Trip is a clinical search engine designed to allow users to quickly and easily find and use high-quality research evidence to support their practice and/or care.

Trip has been online since 1997 and in that time has developed into the internet’s premier source of evidence-based content. Our motto is ‘Find evidence fast’ and this is something we aim to deliver for every single search.

As well as research evidence we also allow clinicians to search across other content types including images, videos, patient information leaflets, educational courses and news.

For further information on Trip click on any of the questions/sections on the left-hand side of this page. But if you still have questions please contact us via jon.brassey@tripdatabase.com

Top results for multiple sclerosis

1. ADSTEP: Preliminary Investigation of a Multicomponent Walking Aid Program in People With Multiple Sclerosis

ADSTEP: Preliminary Investigation of a Multicomponent Walking Aid Program in People With Multiple Sclerosis 29958906 2018 09 29 1532-821X 99 10 2018 Oct Archives of physical medicine and rehabilitation Arch Phys Med Rehabil ADSTEP: Preliminary Investigation of a Multicomponent Walking Aid Program in People With Multiple Sclerosis. 2050-2058 S0003-9993(18)30382-4 10.1016/j.apmr.2018.05.023 To evaluate the effect of the Assistive Device Selection, Training and Education Program (ADSTEP) on falls (...) and walking and sitting activity in people with multiple sclerosis (PwMS). Randomized controlled trial. Veterans affairs medical center. PwMS (N=40) using a walking aid at baseline who had fallen in the previous year. Participants were randomly assigned to ADSTEP or control. ADSTEP had 6 weekly, 40-minute, 1-on-1 sessions with a physical therapist, starting with walking aid selection and fitting, followed by task-oriented progressive gait training. Control was usual medical care with the option of ADSTEP

EvidenceUpdates2018

3. Information provision for people with multiple sclerosis.

Information provision for people with multiple sclerosis. BACKGROUND: People with multiple sclerosis (MS) are confronted with a number of important uncertainties concerning many aspects of the disease. These include diagnosis, prognosis, disease course, disease-modifying therapies, symptomatic therapies, and non-pharmacological interventions, among others. While people with MS demand adequate information to be able to actively participate in medical decision making and to self manage (...) their disease, it has been shown that patients' disease-related knowledge is poor, therefore guidelines recommend clear and concise high-quality information at all stages of the disease. Several studies have outlined communication and information deficits in the care of people with MS. However, only a few information and decision support programmes have been published. OBJECTIVES: The primary objectives of this updated review was to evaluate the effectiveness of information provision interventions

Cochrane2018

4. Multiple sclerosis

Multiple sclerosis Multiple sclerosis - Symptoms, diagnosis and treatment | BMJ Best Practice You'll need a subscription to access all of BMJ Best Practice Search  Multiple sclerosis Last reviewed: September 2018 Last updated: October 2018 Important updates New daclizumab alert: encephalitis cases reported several months after discontinuation Prescribers are being advised to contact patients who have discontinued daclizumab to ensure they are aware of the symptoms of immune-mediated (...) dysfunction. Definition Multiple sclerosis (MS) is defined as an inflammatory demyelinating disease characterised by the presence of episodic neurological dysfunction in at least 2 areas of the central nervous system (brain, spinal cord, and optic nerves) separated in time and space. Polman CH, Reingold SC, Edan G, et al. Diagnostic criteria for multiple sclerosis: 2005 revisions to the "McDonald Criteria". Ann Neurol. 2005 Dec;58(6):840-6. http://onlinelibrary.wiley.com/doi/10.1002/ana.20703/full http

BMJ Best Practice2018

5. Discriminative ability and clinical utility of the Timed Up and Go (TUG) in identifying falls risk in people with multiple sclerosis: a prospective cohort study

Discriminative ability and clinical utility of the Timed Up and Go (TUG) in identifying falls risk in people with multiple sclerosis: a prospective cohort study 30103642 2018 08 14 1477-0873 2018 Aug 14 Clinical rehabilitation Clin Rehabil Discriminative ability and clinical utility of the Timed Up and Go (TUG) in identifying falls risk in people with multiple sclerosis: a prospective cohort study. 269215518793481 10.1177/0269215518793481 To investigate discriminative ability and clinical (...) utility of the Timed Up and Go under single- and dual-task conditions between fallers and non-fallers in multiple sclerosis (MS). Prospective cohort study. Neurology service in a tertiary hospital. Participants were 101 people with MS and Expanded Disability Status Scale score of 3-6.5. One participant withdrew after the baseline assessment, and hence the data were analysed for 100 participants. No specific intervention. Timed Up and Go and Timed Up and Go-Cognitive. Three-month prospective diaries

EvidenceUpdates2018

6. Relationship Between Physiological and Perceived Fall Risk in People With Multiple Sclerosis: Implications for Assessment and Management

Relationship Between Physiological and Perceived Fall Risk in People With Multiple Sclerosis: Implications for Assessment and Management 29698641 2018 09 29 1532-821X 99 10 2018 Oct Archives of physical medicine and rehabilitation Arch Phys Med Rehabil Relationship Between Physiological and Perceived Fall Risk in People With Multiple Sclerosis: Implications for Assessment and Management. 2022-2029 S0003-9993(18)30238-7 10.1016/j.apmr.2018.03.019 This study evaluated the relationship between (...) physiological and perceived fall risk in people with multiple sclerosis (MS). Secondary analysis of data from prospective cohort studies undertaken in Australia, the United Kingdom, and the United States. Community. Ambulatory people with MS (N=416) (age 51.5±12.0 years; 73% female; 62% relapsing-remitting MS; 13.7±9.9 years disease duration). Not applicable. All participants completed measures of physiological (Physiological Profile Assessment [PPA]) and perceived (Falls Efficacy Scale-international [FESi

EvidenceUpdates2018

7. Diagnostic and Clinical Utility of the GAD-2 for Screening Anxiety Symptoms in Individuals With Multiple Sclerosis

Diagnostic and Clinical Utility of the GAD-2 for Screening Anxiety Symptoms in Individuals With Multiple Sclerosis 29964000 2018 10 02 1532-821X 99 10 2018 Oct Archives of physical medicine and rehabilitation Arch Phys Med Rehabil Diagnostic and Clinical Utility of the GAD-2 for Screening Anxiety Symptoms in Individuals With Multiple Sclerosis. 2045-2049 S0003-9993(18)30390-3 10.1016/j.apmr.2018.05.029 To assess the diagnostic and clinical utility of the 2-item Generalized Anxiety Disorder (...) Scale (GAD-2) for screening anxiety symptoms in individuals with multiple sclerosis (MS). Cross-sectional. University-affiliated MS neurology and rehabilitation center. The sample comprised adults (N=99) (ages 19-72; mean ± SD=46.2±13.0; 75% women) with a physician-confirmed MS diagnosis who were receiving care in a university-affiliated MS center. Disease durations ranged from 1 to 37 years (mean ± SD=10.7±8.4). Not applicable. Participants completed the 7-item Generalized Anxiety Disorder Scale

EvidenceUpdates2018

8. Vitamin D for the management of multiple sclerosis.

Vitamin D for the management of multiple sclerosis. BACKGROUND: This review is an update of a previously published review, "Vitamin D for the management of multiple sclerosis" (published in the Cochrane Library; 2010, Issue 12). Multiple sclerosis (MS) is characterised by inflammation, demyelination, axonal or neuronal loss, and astrocytic gliosis in the central nervous system (CNS), which can result in varying levels of disability. Some studies have provided evidence showing an association (...) of MS with low levels of vitamin D and benefit derived from its supplementation. OBJECTIVES: To evaluate the benefit and safety of vitamin D supplementation for reducing disease activity in people with MS. SEARCH METHODS: We searched the Cochrane Multiple Sclerosis and Rare Diseases of the CNS Specialized Register up to 2 October 2017 through contact with the Information Specialist with search terms relevant to this review. We included references identified from comprehensive electronic database

Cochrane2018

9. Trial of Fingolimod versus Interferon Beta-1a in Pediatric Multiple Sclerosis.

Trial of Fingolimod versus Interferon Beta-1a in Pediatric Multiple Sclerosis. BACKGROUND: Treatment of patients younger than 18 years of age with multiple sclerosis has not been adequately examined in randomized trials. We compared fingolimod with interferon beta-1a in this population. METHODS: In this phase 3 trial, we randomly assigned patients 10 to 17 years of age with relapsing multiple sclerosis in a 1:1 ratio to receive oral fingolimod at a dose of 0.5 mg per day (0.25 mg per day (...) (absolute difference, 0.55 relapses; relative difference, 82%; P<0.001). The key secondary end point of the annualized rate of new or newly enlarged lesions on T 2 -weighted magnetic resonance imaging (MRI) was 4.39 with fingolimod and 9.27 with interferon beta-1a (absolute difference, 4.88 lesions; relative difference, 53%; P<0.001). Adverse events, excluding relapses of multiple sclerosis, occurred in 88.8% of patients who received fingolimod and 95.3% of those who received interferon beta-1a

NEJM2018

10. Phase 2 Trial of Ibudilast in Progressive Multiple Sclerosis.

Phase 2 Trial of Ibudilast in Progressive Multiple Sclerosis. BACKGROUND: There are limited treatments for progressive multiple sclerosis. Ibudilast inhibits several cyclic nucleotide phosphodiesterases, macrophage migration inhibitory factor, and toll-like receptor 4 and can cross the blood-brain barrier, with potential salutary effects in progressive multiple sclerosis. METHODS: We enrolled patients with primary or secondary progressive multiple sclerosis in a phase 2 randomized trial of oral (...) in multiple sclerosis. RESULTS: Of 255 patients who underwent randomization, 129 were assigned to ibudilast and 126 to placebo. A total of 53% of the patients in the ibudilast group and 52% of those in the placebo group had primary progressive disease; the others had secondary progressive disease. The rate of change in the brain parenchymal fraction was -0.0010 per year with ibudilast and -0.0019 per year with placebo (difference, 0.0009; 95% confidence interval, 0.00004 to 0.0017; P=0.04), which represents

NEJM2018

12. Subcutaneous ofatumumab in patients with relapsing-remitting multiple sclerosis: The MIRROR study

Subcutaneous ofatumumab in patients with relapsing-remitting multiple sclerosis: The MIRROR study 29695594 2018 05 20 1526-632X 90 20 2018 May 15 Neurology Neurology Subcutaneous ofatumumab in patients with relapsing-remitting multiple sclerosis: The MIRROR study. e1805-e1814 10.1212/WNL.0000000000005516 To assess dose-response effects of the anti-CD20 monoclonal antibody ofatumumab on efficacy and safety outcomes in a phase 2b double-blind study of relapsing forms of multiple sclerosis (RMS (...) .), and Modeling and Simulation (D.J.A.), GlaxoSmithKline, Uxbridge, Middlesex, UK; Neurosciences Therapy Area Unit (J.M.T., S.A.V., E.W.L., F.J.D., M.C.L., S.T.K.), SAVM (F.J.D., M.C.L.), Global Clinical Safety and Pharmacovigilance (E.W.L.), and Neurosciences Clinical Statistics (SecTK), GlaxoSmithKline, Research Triangle Park, NC; Department of Neurology (A.E.M.), Corinne Goldsmith Dickinson Center for Multiple Sclerosis, Icahn School of Medicine at Mount Sinai, New York, NY; and Danish Multiple Sclerosis

EvidenceUpdates2018 Full Text: Link to full Text with Trip Pro

13. Moderators of Treatment Outcomes After Telehealth Self-Management and Education in Adults With Multiple Sclerosis: A Secondary Analysis of a Randomized Controlled Trial

Moderators of Treatment Outcomes After Telehealth Self-Management and Education in Adults With Multiple Sclerosis: A Secondary Analysis of a Randomized Controlled Trial 29337024 2018 06 25 1532-821X 99 7 2018 Jul Archives of physical medicine and rehabilitation Arch Phys Med Rehabil Moderators of Treatment Outcomes After Telehealth Self-Management and Education in Adults With Multiple Sclerosis: A Secondary Analysis of a Randomized Controlled Trial. 1265-1272 S0003-9993(18)30007-8 10.1016 (...) /j.apmr.2017.12.012 To examine moderators of treatment effects in a randomized controlled trial comparing a telehealth self-management intervention with a telehealth multiple sclerosis (MS) education intervention for fatigue, pain, and mood in adults with MS. Secondary analysis of a single-blind randomized controlled trial. Community. Adults with MS and chronic fatigue, chronic pain, and/or moderate depressive symptoms (N=163) recruited from across the United States. Two 8-week, telephone-delivered

EvidenceUpdates2018

15. Multiple sclerosis

Multiple sclerosis Top results for multiple sclerosis - Trip Database or use your Google+ account Find evidence fast My query is: English Français Deutsch Čeština Español Magyar Svenska ALL of these words: Title only Anywhere in the document ANY of these words: Title only Anywhere in the document This EXACT phrase: Title only Anywhere in the document EXCLUDING words: Title only Anywhere in the document Timeframe: to: Combine searches by placing the search numbers in the top search box (...) and pressing the search button. An example search might look like (#1 or #2) and (#3 or #4) Loading history... Population: Intervention: Comparison: Outcome: Population: Intervention: Latest & greatest articles for multiple sclerosis The Trip Database is a leading resource to help health professionals find trustworthy answers to their clinical questions. Users can access the latest research evidence and guidance to answer their clinical questions. We have a large collection of systematic reviews, clinical

Trip Latest and Greatest2018

17. Investigating the combined effect of pelvic floor muscle exercise and mindfulness on sexual function in women with multiple sclerosis: a randomized controlled trial

Investigating the combined effect of pelvic floor muscle exercise and mindfulness on sexual function in women with multiple sclerosis: a randomized controlled trial 29843529 2018 05 30 1477-0873 2018 May 01 Clinical rehabilitation Clin Rehabil Investigating the combined effect of pelvic floor muscle exercise and mindfulness on sexual function in women with multiple sclerosis: a randomized controlled trial. 269215518777877 10.1177/0269215518777877 To evaluate the combined effect of pelvic floor (...) muscle exercise and mindfulness on sexual function in women with multiple sclerosis. It was a three-arm parallel randomized clinical trial study. Outpatient clinic. Patients with multiple sclerosis. Participants in the intervention groups completed an eight-week program consisting of pelvic floor muscle exercise, mindfulness, and pelvic floor muscle exercise along with mindfulness. The main measure was the Female Sexual Function Index. In total, 70 patients completed the study. The results showed

EvidenceUpdates2018

19. Multiple sclerosis: a drug that should never have been authorised

Multiple sclerosis: a drug that should never have been authorised Prescrire IN ENGLISH - Spotlight ''Multiple sclerosis: a drug that should never have been authorised'', 1 July 2018 {1} {1} {1} | | > > > Multiple sclerosis: a drug that should never have been authorised Spotlight Every month, the subjects in Prescrire’s Spotlight. 100 most recent :  |   |   |   |   |   |   |   |   |  Spotlight Multiple sclerosis: a drug (...) that should never have been authorised In March 2018, after several deaths, daclizumab (Zinbryta°) was withdrawn from the market. The European Medicines Agency should never have authorised this drug. In patients with multiple sclerosis, interferon beta is the first-choice treatment, for want of a better option. Despite the severity of multiple sclerosis in some patients, there is no justification for exposing them to drugs such as alemtuzumab, natalizumab or teriflunomide, whose harm-benefit balance

Prescrire2018

20. Effectiveness of virtual reality training for balance and gait rehabilitation in people with multiple sclerosis: a systematic review and meta-analysis

Effectiveness of virtual reality training for balance and gait rehabilitation in people with multiple sclerosis: a systematic review and meta-analysis 29651873 2018 04 13 1477-0873 2018 Apr 01 Clinical rehabilitation Clin Rehabil Effectiveness of virtual reality training for balance and gait rehabilitation in people with multiple sclerosis: a systematic review and meta-analysis. 269215518768084 10.1177/0269215518768084 To evaluate the evidence for the use of virtual reality to treat balance (...) and gait impairments in multiple sclerosis rehabilitation. Systematic review and meta-analysis of randomized controlled trials and quasi-randomized clinical trials. An electronic search was conducted using the following databases: MEDLINE (PubMed), Physiotherapy Evidence Database (PEDro), Cochrane Database of Systematic Reviews (CDSR) and (CINHAL). A quality assessment was performed using the PEDro scale. The data were pooled and a meta-analysis was completed. This systematic review was conducted

EvidenceUpdates2018